An experimental GLP-1 pill developed by Structure Therapeutics, known as GSBR-1290, has shown significant promise in aiding weight loss among individuals with obesity or who are overweight. In a Phase 2a study involving 64 healthy participants, those treated with GSBR-1290 experienced an average reduction in body weight of 6.2% over those given a placebo. Notably, one-third of the participants on the drug lost 10% or more of their body weight, a result not seen in the placebo group.
The positive outcomes have led to a surge in Structure's stock value, marking a rebound from previous disappointments. The company is now preparing to initiate a 36-week Phase 2b obesity study in the fourth quarter, aiming to explore higher doses of GSBR-1290. This move is part of Structure's broader ambition to compete with existing GLP-1 drugs for diabetes and weight loss, such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, by offering an oral treatment alternative.
Common side effects associated with GSBR-1290 included nausea and vomiting, which were reported to lessen over time with dose adjustments. Despite these side effects, the drug's safety profile was affirmed with no cases of liver injury or persistent increases in liver enzymes reported. Analysts have highlighted the potential for small molecule pills like GSBR-1290 to offer a more convenient and cost-effective treatment option compared to injectable alternatives.
Structure's CEO, Raymond Stevens, expressed optimism about the future of GSBR-1290, stating the company's belief in the potential to explore higher doses in subsequent studies. This development represents a significant step forward in the search for effective oral treatments for obesity, a condition that affects millions worldwide.
